The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
Open accessAbstract
Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications
Krueger, F., & Andrews, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr167 · Cited by 5,275
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–317 of 317
Functional enhancers: concept, screening, and validation
Lin, H., Chen, F., & Huang, J. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0113
Gao, Y., Liu, Y., Ye, X., Liu, A., Hu, S., Li, X., Mo, L. D., Jiang, L., Ma, Q., Zheng, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5633850
Additional file 1 of Functional mapping of androgen receptor enhancer activity
Huang, C.-C. F., Lingadahalli, S., Morova, T., Özturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., Sar, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14576597
Additional file 2 of Functional mapping of androgen receptor enhancer activity
Huang, C.-C. F., Lingadahalli, S., Morova, T., Özturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., Sar, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14576600
Additional file 4 of Functional mapping of androgen receptor enhancer activity
Huang, C.-C. F., Lingadahalli, S., Morova, T., Özturan, D., Hu, E., Yu, I. P. L., Linder, S., Hoogstraat, M., Stelloo, S., Sar, F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14576606
Guo, J., Wei, Z., Jia, T., Wang, L., Nama, N., Liang, J., Liao, X., Liu, X., Gao, Y., Liu, X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24303332
Paakinaho, V., Sutinen, P., Malinen, M., & Palvimo, J. J. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_12-2
Guo, S., Xu, X., Li, G., Yang, Y., Yan, Z., Wang, X., Jing, P., Zhou, Y., Jia, M., Wang, Y., et al. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag072
MRE11 proximal polyadenylation site-mediated looping impacts transcription and genomic stability
Huang, K., Brault, M. E., Cong, K., Azazmeh, N., Collins, S., Lee, S., Lantz, G. A., Raskind, G., Legube, G., Beroukhim, R., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.03.032
Epigenetic modulation of prostate cancer disparities in men with African ancestry
Craddock, J., & Hayes, V. M. (2026) · Nature Reviews Urology · doi:10.1038/s41585-026-01157-4
3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer
Qi, S., & Dehm, S. M. (2026) · Endocrinology · doi:10.1210/endocr/bqag068
Gao, Y., Liu, Y., Ye, X., Liu, A., Li, X., Hu, S., Chen, X., Ma, Q., Mo, L., Jiang, L., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03900-y
Siskin, M., Saha, J., Antonarakis, E. S., Leal, A., Parry, S. R., & Wise, D. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188199
Kukkonen, K., Afyounian, E., Rauhala, H. E., Nykter, M., Urbanucci, A., Latonen, L., & Visakorpi, T. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag891
Gao, X., Garmezy, B., Vuky, J., Shen, J., Sartor, O. A., Sternberg, C. N., Dreicer, R., Hussain, M., Kalebasty, A. R., Percent, I. J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02995
Chou, C., Tseng, C., Lin, Y., Wang, M., Chen, P., Chang, D., Cheng‐Huang, S., & Fang, C. (2026) · Cancer Medicine · doi:10.1002/cam4.72365
Metadata
- Authors
- Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., Stillman, D. R., Cejas, P., Qiu, X., Long, H. W., Tisza, V., Nuzzo, P. V., Rohanizadegan, M., Pomerantz, M. M., Hahn, W. C., & Freedman, M. L.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Eötvös Loránd University (HU)
- University of Veterinary Medicine (HU)
- Semmelweis University (HU)
- Boston Children's Hospital (US)
- Corresponding author
- Freedman, Matthew L.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 2
- Pages
- 422-432.e13
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6046260
- OpenAlex
- W2808687910
- Cited by
- 317
- References
- 55
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 44 · 2023: 47 · 2022: 41 · 2021: 54 · 2020: 44 · 2019: 32 · 2018: 10
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Prostate Cancer Foundation Challenge Award
- NIH (R01GM107427, R01CA193910, K08CA218530, R01HG005220, U01 CA176058)
- National Research, Development and Innovation Fund of Hungary Project (FIEK_16-1-2016-0005)
- Novo Nordisk Foundation Interdisciplinary Synergy Programme (NNF15OC0016584)
- European Social Fund (EFOP-3.6.3-VEKOP-16-2017-00005)
- Breast Cancer Research Foundation (BCRF-17-156)
- H.L. Snyder Medical Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- androgen receptor, advanced prostate cancer, treatment resistance, enzalutamide resistance, non-coding regulatory elements, genome editing, epigenetic profiling, oncogenic drivers
- MeSH terms
- Gene Editing, Acetylation, Adult, Aged, Antineoplastic Agents, Benzamides, Cell Survival, Enhancer Elements, Genetic, Histones, Humans, Male, Middle Aged, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Receptors, Androgen, DNA Methylation, Cell Line, Tumor, CRISPR-Cas Systems, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
